Patient P-02508
Therapy response
Declining
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
84%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 72 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 89 ME-01 recommended — Monitoring Escalation ME-01
- Day 90 Patient accepted — Started ME-01 in the companion
- Day 93 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 72.
Primary contributors, last 14 days
- GI instability-14
- Nutritional resilience+13
- Treatment adherence-12
- Inflammatory activity-7
- Toxicity-3
What helped?
- Monitoring Escalation ME-01Day 89Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 88% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 57 and rising
- WearableSleep 5.1 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 41/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 54
- WearableHRV 22 ms, trending down
- Autonomic recovery ↓45
- WearableResting HR 74 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 44
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2 · butyrate capacity 41/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 22 ms
- Sleep
- 5.2 h
- Steps
- 6,053
- Resting HR
- 76 bpm
Daily log: GI score 57, nutritional resilience 43, adherence 56.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.